- Home
- AUTL vs PLRX Comparison
AUTL vs PLRX Comparison
Compare AUTL & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | PLRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 93.3M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AUTL | PLRX |
|---|---|---|
| Price | $1.91 | $1.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 11 |
| Target Price | ★ $8.67 | $3.79 |
| AVG Volume (30 Days) | ★ 2.6M | 945.1K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,128,000.00 | N/A |
| Revenue This Year | $669.49 | N/A |
| Revenue Next Year | $91.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 406.67 | N/A |
| 52 Week Low | $1.11 | $1.10 |
| 52 Week High | $2.70 | $13.46 |
Technical Indicators
Market Signals| Indicator | AUTL | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.96 | 49.88 |
| Support Level | $1.77 | $1.20 |
| Resistance Level | $2.07 | $1.36 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 69.90 | 73.53 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.